Cargando…
Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery
The large amount of data that has been collected so far for G protein-coupled receptors requires machine learning (ML) approaches to fully exploit its potential. Our previous ML model based on gradient boosting used for prediction of drug affinity and selectivity for a receptor subtype was compared...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071054/ https://www.ncbi.nlm.nih.gov/pubmed/33920024 http://dx.doi.org/10.3390/ijms22084060 |
_version_ | 1783683611447263232 |
---|---|
author | Mizera, Mikołaj Latek, Dorota |
author_facet | Mizera, Mikołaj Latek, Dorota |
author_sort | Mizera, Mikołaj |
collection | PubMed |
description | The large amount of data that has been collected so far for G protein-coupled receptors requires machine learning (ML) approaches to fully exploit its potential. Our previous ML model based on gradient boosting used for prediction of drug affinity and selectivity for a receptor subtype was compared with explicit information on ligand-receptor interactions from induced-fit docking. Both methods have proved their usefulness in drug response predictions. Yet, their successful combination still requires allosteric/orthosteric assignment of ligands from datasets. Our ligand datasets included activities of two members of the secretin receptor family: GCGR and GLP-1R. Simultaneous activation of two or three receptors of this family by dual or triple agonists is not a typical kind of information included in compound databases. A precise allosteric/orthosteric ligand assignment requires a continuous update based on new structural and biological data. This data incompleteness remains the main obstacle for current ML methods applied to class B GPCR drug discovery. Even so, for these two class B receptors, our ligand-based ML model demonstrated high accuracy (5-fold cross-validation Q(2) > 0.63 and Q(2) > 0.67 for GLP-1R and GCGR, respectively). In addition, we performed a ligand annotation using recent cryogenic-electron microscopy (cryo-EM) and X-ray crystallographic data on small-molecule complexes of GCGR and GLP-1R. As a result, we assigned GLP-1R and GCGR actives deposited in ChEMBL to four small-molecule binding sites occupied by positive and negative allosteric modulators and a full agonist. Annotated compounds were added to our recently released repository of GPCR data. |
format | Online Article Text |
id | pubmed-8071054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80710542021-04-26 Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery Mizera, Mikołaj Latek, Dorota Int J Mol Sci Article The large amount of data that has been collected so far for G protein-coupled receptors requires machine learning (ML) approaches to fully exploit its potential. Our previous ML model based on gradient boosting used for prediction of drug affinity and selectivity for a receptor subtype was compared with explicit information on ligand-receptor interactions from induced-fit docking. Both methods have proved their usefulness in drug response predictions. Yet, their successful combination still requires allosteric/orthosteric assignment of ligands from datasets. Our ligand datasets included activities of two members of the secretin receptor family: GCGR and GLP-1R. Simultaneous activation of two or three receptors of this family by dual or triple agonists is not a typical kind of information included in compound databases. A precise allosteric/orthosteric ligand assignment requires a continuous update based on new structural and biological data. This data incompleteness remains the main obstacle for current ML methods applied to class B GPCR drug discovery. Even so, for these two class B receptors, our ligand-based ML model demonstrated high accuracy (5-fold cross-validation Q(2) > 0.63 and Q(2) > 0.67 for GLP-1R and GCGR, respectively). In addition, we performed a ligand annotation using recent cryogenic-electron microscopy (cryo-EM) and X-ray crystallographic data on small-molecule complexes of GCGR and GLP-1R. As a result, we assigned GLP-1R and GCGR actives deposited in ChEMBL to four small-molecule binding sites occupied by positive and negative allosteric modulators and a full agonist. Annotated compounds were added to our recently released repository of GPCR data. MDPI 2021-04-14 /pmc/articles/PMC8071054/ /pubmed/33920024 http://dx.doi.org/10.3390/ijms22084060 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mizera, Mikołaj Latek, Dorota Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title | Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title_full | Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title_fullStr | Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title_full_unstemmed | Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title_short | Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery |
title_sort | ligand-receptor interactions and machine learning in gcgr and glp-1r drug discovery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071054/ https://www.ncbi.nlm.nih.gov/pubmed/33920024 http://dx.doi.org/10.3390/ijms22084060 |
work_keys_str_mv | AT mizeramikołaj ligandreceptorinteractionsandmachinelearningingcgrandglp1rdrugdiscovery AT latekdorota ligandreceptorinteractionsandmachinelearningingcgrandglp1rdrugdiscovery |